To see the demo, download it here: http://www.consultparagon.com/webinar-driving-innovation-through-licensing-competitive-intelligence-and-big-data-analytics.html Today’s pharmaceutical companies are in a competitive brawl to rapidly identify, value and license promising drug candidates from external sources. This requires a significant investment in time and money, with no guarantee of success. To identify product opportunities ahead of a competitor requires a unique blend of competitive intelligence, advanced search and qualification technology, and the ability to quickly and accurately value a potential investment. In this session, you will learn how to maximize the investment in time spent searching, qualifying and valuing new assets. This approach offers competitive advantage by putting key information used to decide whether to accelerate, abandon or hold on an opportunity at licensing and acquisitions executives’ fingertips.

1. Driving Innovation through Licensing,
Competitive Intelligence and
Big Data Analytics
John D’Antonio,
Director, Life Sciences Advisory Services,
Licensing & Competitive Intelligence
Rick Ruiz
Director, Practice Leader
Information Integration & Analytics
1

2. About Paragon
Leading mid-tier information solutions
company that helps firms leverage
assets to maximize business results.
 Deep Pharmaceutical and Life sciences industry expertise
 Solution competencies for process optimization, channel
and supply chain, analytics, licensing, information
management
 Advisory services consulting and execution delivering
Corporate Facts practical business value
• National Coverage
• Global Clients  Industry-aligned accelerators provide rapid time-to-value
• NJ Headquarters
and lower total cost of ownership.
• Dual-shore Development
• CAGR 20+%
• Privately owned, 30-year history  A proven delivery track record and return on investment

3. The Problem
Rapidly finding and screening assets
• Search highly manual, extremely time consuming
• No comprehensive overview to find useful
information
• Unapparent connections between topics hidden
Missed opportunities
• Drug companies late in the game, then overpay
• Differentiation and positioning weakened
• Competition gets in first
• Retrieving complex data from multiple disparate
locations a costly bottleneck

4. The Opportunity
4

5. Significance

6. The Value
6

7. Opportunity Assessment Team
CEO
Finance • EPS R&D
• Valuation • Pipeline • Pipeline
• Risk • Competitors • Efficacy
• Operating • Utility
BD&L Income IP
• Fit & Closure • Royalties
• Timing • Patent Validity
• Potential • Infringement
Manufacturing Clinical &
• Scalability Regulatory
• Complexity • Pathway
• Batch Cost • Development
Cost
• Approval

8. Partnerships
Analytic Technology
Paragon Orchestrated Solution
Semantic Intelligence Engine
Drug Chemistry
Cortellis Industry Data
Financial Decision Analysis

9. Demo

10. Questions???

11. Thank You
John D’Antonio,
Director, Life Sciences Advisory Services,
Licensing & Competitive Intelligence
jdantonio@consultparagon.com
mobile: 609-577-0755
Rick Ruiz
Director, Practice Leader
Information Integration & Analytics
rruiz@consultparagon.com
mobile: 732.535.1920